Literature DB >> 10072418

Managing psychosis in patients with Parkinson's disease.

J L Cummings.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10072418     DOI： 10.1056/NEJM199903113401011

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up.

Authors:  P Pollak; F Tison; O Rascol; A Destée; J J Péré; J M Senard; F Durif; I Bourdeix
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

2.  Quetiapine in the treatment of psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Mike Samuel; Anthony David
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

3.  Behavioural and psychological symptoms of dementia associated with Parkinson's disease.

Authors:  I Leroi; A Burns
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-09-05       Impact factor: 10.154

4.  Sleep disorders and daytime sleepiness in Parkinson's disease.

Authors:  Renee Monderer; Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2009-03       Impact factor: 5.081

Review 5.  Dementia with Lewy bodies: clinical features and treatment.

Authors:  S Campbell; S Stephens; C Ballard
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Psychosis Due to Neurologic Conditions.

Authors:  David B. Arciniegas; Jeannie L. Topkoff; Kerri Held; Lauren Frey
Journal:  Curr Treat Options Neurol       Date:  2001-07       Impact factor: 3.598

Review 7.  Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.

Authors:  Ketan Dipak Jethwa; Oluwademilade A Onalaja
Journal:  BJPsych Open       Date:  2015-07-24

8.  A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

Authors:  Paul Shotbolt; Michael Samuel; Chris Fox; Anthony S David
Journal:  Neuropsychiatr Dis Treat       Date:  2009-06-10       Impact factor: 2.570
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.